Oncoclínicas clears creditor threshold for debt revamp, backed by earlier $29.9M lifeline
What's the deal? Brazilian cancer-care provider Grupo OncoclínicasDealroom has a profile for this one. Try Dealroom → has won support from creditors holding about 70% of its debt for an out-of-court restructuring, clearing the 50% threshold needed for court approval. The plan centers on longer repayment terms and smaller haircuts on US$1.3B in debt.
The backstory: As the company's financial crisis deepened, it secured US$38.4M (≈$29.9 million) in financing from asset manager LuminaDealroom has a profile for this one. Try Dealroom → to fund drug purchases. The cash came after Oncoclínicas delayed care for roughly 6,000 patients between March and April, lacking money to buy medicines — a serious reputational blow.
Why now? The company faced a Friday deadline to present the outcome of negotiations. That threshold was reached with the backing of real estate receivables certificate (CRI) holders and pharmaceutical distributor OncoprodDealroom has a profile for this one. Try Dealroom →.
What's in the plan? The largest financial creditors are expected to get repayment terms of around 13 years, including a grace period of one to two years, according to people familiar with the matter. Specific conditions will vary by creditor.
The supplier deal: Oncoprod, owed roughly US$307M, negotiated separate terms given its critical role supplying medicines. It will face no haircut, begin receiving payments in 2027, and resume supplying drugs on 90-day terms up to US$153.5M.
What could go wrong? Oncoclínicas also faces a shareholder dispute over a potential tender offer that could reach US$3.58B. Minority shareholders led by LatacheDealroom has a profile for this one. Try Dealroom → want it to proceed, while CentaurusDealroom has a profile for this one. Try Dealroom → — which would have to buy the shares — has launched arbitration, arguing disputes must go through B3's arbitration chamber.
The signal: Court approval could revive investor interest in a company that once drew backers including Goldman SachsDealroom has a profile for this one. Try Dealroom →, which controlled 93% before its 2021 IPO and has since unwound its position. A July proposal from asset manager IG4Dealroom has a profile for this one. Try Dealroom → to lead the restructuring, including a US$127.9M convertible debenture subscription, remains on hold.
Read more: valorinternational.globo.com
Image credit: Phil and Pam
